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Inflammation is widely recognized as an inducer of cancer pro-
gression. The inflammation-associated enzyme, inducible nitric
oxide synthase (NOS2), has emerged as a candidate oncogene in
estrogen receptor (ER)-negative breast cancer, and its increased
expression is associated with disease aggressiveness and poor
survival. Although these observations implicate NOS2 as an
attractive therapeutic target, the mechanisms of both NOS2
induction in tumors and nitric oxide (NO)-driven cancer progression
are not fully understood. To enhance our mechanistic understanding
of NOS2 induction in tumors and its role in tumor biology, we used
stimulants of NOS2 expression in ER− and ER+ breast cancer cells and
examined downstream NO-dependent effects. Herein, we show that
up-regulation of NOS2 occurs in response to hypoxia, serum with-
drawal, IFN-γ, and exogenous NO, consistent with a feed-forward
regulation of NO production by the tumor microenvironment in
breast cancer biology. Moreover, we found that key indicators of
an aggressive cancer phenotype including increased S100 calcium
binding protein A8, IL-6, IL-8, and tissue inhibitor matrix metallopro-
teinase-1 are up-regulated by these NOS2 stimulants, whereas in-
hibition of NOS2 in MDA-MB-231 breast cancer cells suppressed
these markers. Moreover, NO altered cellular migration and chemo-
resistance of MDA-MB-231 cells to Taxol. Most notably, MDA-MB-
231 tumor xenographs and cell metastases from the fat pad to the
brain were significantly suppressed by NOS2 inhibition in nude mice.
In summary, these results link elevated NOS2 to signals from the
tumor microenvironment that arise with cancer progression and
show that NO production regulates chemoresistance and metastasis
of breast cancer cells.
Inflammation is a major component of the tumor microenvi-ronment and a driving force in cancer initiation, promotion,
and progression (1–3). Epithelial cancers express markers of
inflammation that promote disease progression and drug re-
sistance through evasion of cell death pathways and increased
tumor metastasis. Rapid cancer growth leads to tumor hypoxia
and nutrient deprivation, which promotes chronic inflammatory
feed-forward signaling and selection of resistant tumors that are
clinically challenging and sometimes untreatable.
Several proinflammatory proteins such as COX2, NF-κB, IL-6,
IL-8, S100 calcium binding protein A8 (S100A8), and VEGF are
markers of chronic inflammation in the tumor microenvironment.
In addition, these proinflammatory mediators directly correlate with
inducible nitric oxide synthase (NOS2), which is an emerging bio-
marker of aggressive tumors that predicts poor survival in patients
with elevated tumor NOS2 expression (4–8). These and other
clinical studies warrant an improved mechanistic understanding of
intratumoral NOS2 regulation and endogenous NO production,
which may be therapeutically beneficial.
Toward this end, our laboratory and others have used NO
donors to study NO signaling in cancer. However, intratumoral
NOS2 induction by components of the tumor microenvironment,
which produces endogenous NO at levels that promote disease
progression and predict poor outcome, has not been examined.
Herein, we have used cell culture conditions that simulate
chronic inflammation in the tumor microenvironment, which
include nutrient deprivation by serum withdrawal (SW), hypoxia,
inflammatory cytokines, and NO donors to examine physiologic
mechanisms of NOS2 induction and downstream effects of NO
target activation in both estrogen receptor positive and negative
(ER+ and ER−) breast cancer cells. In addition, we show in vivo
effects of NOS2 inhibition on tumor growth and metastases in
mice. Using this approach, we provide evidence of NOS2 as a key
driver of feed-forward signaling that promotes chronic inflam-
mation and cancer progression.
Results
NOS2 Drives Tumor Growth and Metastasis. The effects of NOS2
inhibiton via amminoguanidine (AG) on tumor progression was
examined in a xenograph model of green fluorescent protein-
tagged MDA-MB-231 (MDA-MB-231-GFP) breast cancer cells
implanted in the mammary fat pad of female nude mice. Fig. 1
demonstrates significantly reduced tumor growth in AG-treated
mice (Fig. 1A); after 37 d of treatment, AG suppressed tumor
growth by 59% compared with control (44.9 ± 8.8 mm3 vs. 109 ± 17
mm3, respectively). These results are supported by GFP fluores-
cence imaging shown in Fig. 1B, which provides a visual index of
reduced tumor cell proliferation in AG-treated mice compared
with control animals.
The effect of NOS2 inhibition on metastatic potential of
MDA-MB-231-GFP tumors was also examined. MDA-MB-231-GFP
cell brain metastasis at day 45 after fat pad injection was quan-
tified by real-time PCR and fluorescence imaging of the GFP
tag. Fig. 1 C and D shows a dramatic reduction in the quantified
mRNA and fluorescent protein levels, respectively of GFP from
the metastasized MDA-MB-231-GFP cells in the brains of
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AG-treated mice compared with control animals. Together, these
results demonstrate that NOS2 inhibition dramatically reduces
tumor growth and metastasis and provides evidence that NOS2 is
a key driver of breast cancer disease progression in this model.
ER− patients with high NOS2 tumor levels were found to have
a gene signature that was predictive of outcome (4). Genes in-
cluded in in this signature were IL-8, IL-6, S100A8, CD44, and
Toll-like receptor 4 (TLR4), all of which are activated by NO
donors in ER− cell lines. To investigate the effect of AG on this
gene signature, we analyzed their expression in dissected tumors
from this model by RT-PCR. As seen in Fig. 1E, the mRNA ex-
pression of COX2, TLR4, S100A8, CD44, IL-6, and IL-8 all sig-
nificantly decrease in AG-treated mice compared with control.
Therefore, this model mimics the patient data and shows NOS2
inhibition reduces markers that are associated with poor outcome.
Cell Migration. Earlier reports have demonstrated NO-induced
migration of ER− breast cancer cells (4). To examine a role of
NO in MDA-MB-231 cell migration induced by SW, we used the
xCelligence RTCA instrument that measures cell movement
in real time. The cells were plated in serum-free RPMI 1640 in the
presence of L-Arg and allowed to adhere overnight. AG was added
with or without varying concentrations of the NO donor 1-[N-
(2-Aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-
diolate (DETA/NO, 100 μM or 300 μM), and real-time migration
of the cells to serum containing media was monitored for 60 h.
Fig. 1F shows abolished cell mobility by AG compared with con-
trol cells. Titration of 100 μM DETA/NO reversed the effects of
AG and increased cell migration of AG-inhibited cells over 24 h,
which returned to baseline levels and is consistent with the tem-
poral release of 100 nM steady-state NO flux released by 100 μM
DETA/NO under the same conditions (Fig. S1). In contrast,
300 μM DETA/NO markedly increased cell migration that was
sustained through 60 h. These results suggest NO flux-dependent
regulation of cell migration. Interestingly, SW also induced
NOS2 expression, nitrite production (Fig. S2 A and B), and se-
cretion of prometastatic cytokines such as IL-6 and IL-8, which
was partially inhibited by AG (Fig. S3).
Drug Resistance. Chemoresistance is a recurring clinical problem
in cancer treatment. Because NOS2 predicts poor cancer sur-
vival, its potential contribution to chemoresistance to Taxol was
examined. MDA-MB-231 cells were pretreated by SW (24 h)
with or without AG or DETA/NO, and then exposed to Taxol
(10 nM) for 18 h. The cells were then trypsinized and plated for
survival. Compared with the untreated control, SW abated Taxol
cell killing, which was augmented by 100 μM DETA/NO (Fig.
1G). These results indicate NO-mediated resistance to breast
cancer cell killing by Taxol under conditions of nutrient depri-
vation. Collectively, these results show promotion of tumor
growth, metastasis, and drug resistance by NOS2-derived NO.
Cytokine Stimulation of NOS2. Cytokines that induce NOS2 are
present in the tumor microenvironment. Thus, cytokine-induced
NOS2 expression was examined in breast cancer cell lines. Fig.
S4A demonstrates a twofold increase in NOS2 protein expres-
sion in MCF-7 and MDA-MB-231 but not MDA-MB-468 breast
cancer cells exposed for 24 h to a cytokine mix (CM). NOS2
enzymatic activity was assessed by nitrite levels in the media by
using the Griess assay. Neither MCF-7 nor MDA-MB-231 nitrite
levels changed after 24-h exposure of IFN-γ, IL-1β, TNF-α, or
lipopolysaccharide (LPS) alone. However, nitrite production
significantly increased in MDA-MB-468 cells after 24 h of IFN-γ
or TNF-α (Fig. S4B). CM increased nitrite levels 2.5-, 2-, and
2.8-fold in MCF-7, MDA-MB-231, and MDA-MB-468 cells, re-
spectively, (Fig. S4C), which was inhibited by AG.
The timing of NOS2 mRNA induction was examined for each
CM-stimulated cell line at 4, 24, and 48 h (Fig. S4D). NOS2
mRNA induction in the least aggressive MCF-7 cells peaked at
24 h and was increased 50-fold relative to control. The more
aggressive MDA-MB-231 cells exhibited peak NOS2 expression
at 4 h with a 170-fold increase. Interestingly, NOS2 expression in
the intermediately aggressive MDA-MB-468 cells was similar to
MCF-7 cells with maximal induction at 24 h; however, the rel-
ative increase in NOS2 levels was much greater and peaked at
>4,000-fold above control levels. The human NOS2 gene con-
tains cytokine responsive elements. Accordingly, CM stimulated
Fig. 1. NO effects on MDA-MB-231 cells in vivo and in vitro. (A) Tumor
volume of control and AG-treated GFP-tagged MDA-MB-231 tumor-bearing
mice (n = 10 and 11 at day 37). (B) GFP fluorescence intensity at tumor site in
control and AG-treated mice at day 45. (C and D) Representative brain GFP
mRNA expression and GFP protein fluorescence intensity, respectively, from
MDA-MB-231-GFP cell brain metastasis at day 45 after fat pad injection
in control and AG-treated mice. (E) mRNA levels of COX2, TLR4, S100A8,
CD44, IL-6, and IL-8 in tumors of control and AG-treated mice (day 45). (F)
DETA/NO addition mediates cell migration. (G) Taxol drug resistance (at
10 nM) in MDA-MB-231 cells treated with SW with or without AG and
DETA/NO (±SEM, *P ≤ 0.05, ***P ≤ 0.001).






















NOS2 promoter activity in MCF-7, MDA-MB-231, and MDA-
MB-468 cells increased 2.2-, 4.2-, and 1.7-fold, respectively, as
measured by a luciferase reporter assay (Fig. S4E). It should be
noted that the message level was orders of magnitude higher
than protein expression and nitrite levels and has been docu-
mented in other cell lines, indicating that there is a tight regu-
lation of NOS2 that has not been completely elucidated (9).
However, it has been shown in human DLD-1 cells that cytokines
can up-regulate miRNA-939 (10), which is able to block protein
translation and may be more active in this cell line. The temporal
profile of NOS2 mRNA expression was also different in each cell
line, further emphasizing the importance of understanding how
and when NOS2 is up-regulated, and its impact on the aggressive
phenotype of these different cancer cells.
Nutrient Deprivation by Serum Withdrawal. Nutrient deprivation is
a common feature of rapidly growing tumors. Cancer cells adapt
to nutrient deprivation by altering metabolism, nutrient uptake,
angiogenesis, and autophagy (11, 12). SW of cells grown in cul-
ture mimics nutrient deprivation, and we investigated the effects
of SW on NOS2 expression. Fig. S2B shows significant nitrite
production in MCF-7, MDA-MB-231, and MDA-MB-468 cells
after 24–48 h of SW. NOS2 mRNA levels increased for each cell
line at each time point, with maximal increases of 5.0, 12, and 2.5
in MCF-7, MDA-MB-231, and MDA-MB-468, respectively (Fig.
S2C). NOS2 luciferase promoter activity increased by 1.8-, 4.0-
and 2.1-fold, respectively, in the same cell lines (Fig. S2D). In
addition, NOS2 protein levels increased after 48 h SW for each
cell line (Fig. S2A).
IFN-γ Stimulation. IFN-γ is a well-known mediator of NOS2 gene
expression. IFN-γ alone induced NOS2mRNA in the MDA-MB-
231 cells (Fig. S5A). Moreover, 4-h stimulation with IFN-γ fol-
lowed by SW increased nitrite accumulation at 48 h (Fig. S5B).
NOS2 protein levels increased in response to 4-h IFN-γ treat-
ment followed by SW compared with control (Fig. S5C). In
contrast, type 1 IFN-α or IFN-β failed to up-regulate NOS2
mRNA or protein in these cells, indicating that NOS2 induction
in breast cancer cells is specific to type 2 IFN-γ (Fig. S5 B and C).
Hypoxia. Hypoxia activates various oncogenic and metabolic
pathways (13) and is a hallmark of aggressive tumors (14).
Hypoxia increases HIF-1α stabilization and accumulation and
regulates important inflammatory genes, including NOS2, which
increased in MCF-7 (15) and MDA-MB-231 cells (16) under
hypoxic conditions. We investigated the effect of hypoxia on
NOS2 protein expression by incubating breast cancer cell lines
under 1% O2 with or without SW for 24 h. As seen in Fig. S5D,
protein levels increased in each cell line after 24-h hypoxia
compared with cells maintained in room air and this increase
occurred only in the absence of serum, indicating that cellular
stress in conjunction with hypoxia is required for a prolonged
NOS2 up-regulation.
Together, these results show that hypoxia and nutrient depri-
vation, conditions that arise in the tumor microenvironment with
disease progression and further promote disease progression and
metastatic spread, induce increased NOS2 expression and ac-
tivity in human breast cancer cells.
Regulation of NOS2 by AG.Nitric oxide participates in positive and
negative feedback regulation of NOS2 through diverse mecha-
nisms involving translation (17, 18), posttranslational modifica-
tion, and enzymatic activity (19). The affect of AG on NOS2
induction was examined by confocal microscopy of IFN-γ/SW-
treated MDA-MB-231 cells. Fig. 2A demonstrates basal NOS2
protein fluorescence in the SW control, which significantly in-
creased in both cytoplasmic and nuclear compartments after
IFN-γ treatment. Whereas the addition of AG minimally effected
NOS2 protein expression in IFN-γ treated cells, AG treatment
dramatically reduced baseline NOS2 protein expression compared
with SW-treated MDA-MB-231 cells (Fig. 2 A and B), which
suggests that basal levels of NOS2-derived NO mediate feed-for-
ward NOS2 protein regulation. To examine a potential role of NO
in feed-forward NOS2 regulation, DETA/NO was titrated back
into AG-inhibited MDA-MB-231 cells. Titration with 300–500 μM
DETA/NO increased NOS2 protein (Fig. 2B) and mRNA (Fig.
2C) expression to control levels in AG-inhibited MDA-MB-231
cells. Furthermore, IFN-γ stimulated cells exhibited a 50% re-
duction of NOS2 mRNA after incubation with AG (Fig. 2C).
Together, these results show a requirement of low NO flux
(200–500 nM steady-state NO) for feed-forward NOS2 regu-
lation in aggressive MDA-MB-231 breast cancer cells.
Downstream Targets of NOS. High-NOS2 ER− breast tumors ex-
hibit increased expression of biomarkers, which predict poor
breast cancer survival including IL-8, IL-6, TLR4, and S100A8
(4). To further examine NO regulatory mechanisms of these
biomarkers under conditions simulating a tumor microenviron-
ment, MDA-MB-231 cells were treated with IFN-γ for 4 h, fol-
lowed by 48 h of SW with or without AG. Fig. 3 A and B shows
induction of S100A8 and IL-6 by INF-γ and SW that is abated
by AG. The effect of exogenous NO on AG inhibited S100A8
expression was also examined. Addition of DETA/NO (Fig. 3C)
increased S100A8 mRNA levels in AG-inhibited MDA-MB-231
cells in a biphasic manner with maximal expression occurring at
300 μM DETA/NO (∼400 nM steady-state flux). The endoge-
nous receptor for S100A8 is TLR4. AG abated TLR4 basal ex-
pression and that of IL-8 (Fig. 3 D and E). These results suggest
a role of NO in the regulation and maintenance of these key
tumor biomarkers.
Tissue inhibitor matrix metalloproteinase-1 (TIMP1) is an
additional biomarker that predicts poor breast cancer patient
survival and correlates with increased PI3k/Akt activation in
Fig. 2. Confocal microscopy of NOS2 protein expression in MDA-MB-231–
treated cells. (A) SW and IFN-γ with or without AG-treated cells. (B) SW with
or without AG or 300 μMDETA/NO. (C) AG decreases NOS2mRNA expression
in SW and IFN-γ–treated cells and titration of DETA/NO reestablishes NOS2
mRNA expression to control levels in SW+AG treated cells (±SEM, **P ≤
0.01). (Scale bars: 20 μm.)





























patients with high NOS2 tumor expression (20). TIMP1 ex-
pression and tyrosine nitration (3NT) was examined under con-
ditions of IFN-γ/SW with or without AG. Fig. 3F shows IFN-γ/SW-
induced TIMP1 protein that was abated by AG. Also, immu-
noprecipitated TIMP1 protein exhibited increased 3NT levels.
Toward this end, we have reported maximal TIMP1 nitration at
two tyrosine residues under conditions of ∼400 nM steady-state
NO flux, which maximally activated PI3k/Akt signaling through
interaction with CD63 (20).
Discussion
Elevated tumor NOS2 predicts poor survival in breast and other
types of cancer (4, 5, 21, 22). We used murine tumor xenographs
and cell culture conditions that mimic an aggressive tumor mi-
croenvironment including inflammation (cytokines), nutrient
deprivation (SW), and hypoxia to examine pathways leading
to tumor NOS2 expression and downstream targets of NOS2-
derived NO that predict aggressive tumor phenotypes (4). Using
this approach coupled with pharmacological NOS2 inhibition,
we provide mechanistic evidence strongly supporting a role of
NOS2-derived NO in breast cancer disease progression as de-
fined by enhanced tumor biomarker expression, tumor growth,
and metastatic burden, which are abated by NOS2 inhibition.
The mRNA of predictive biomarkers found in high NOS2 ER−
breast tumors (COX2, TLR4, S100A8, CD44, IL-6, and IL-8)
were decreased by NOS2 inhibition in our mouse model. Col-
lectively, our results implicate NOS2 as a key driver of cancer
progression toward metastatic disease.
In this report, components of the tumor microenvironment
promote NOS2 expression as confirmed by the assessment of
increased NOS2 mRNA, protein, and nitrite production. Under
these conditions, we show up-regulation of NO-targeted bio-
markers (IL-6, IL-8, S100A8/TLR4, and TIMP1) of cancer pro-
gression (4, 20) that promote tumor cell survival, proliferation,
and migration, which are suppressed by NOS2 inhibition. We
also show intracellular mechanisms of NO-mediated feed-
forward NOS2 regulation. Together, these results demonstrate
that the tumor microenvironment comprises an atmosphere
well suited for NOS2 expression and NOS2-derived NO (Fig. 4),
which are important for maintenance and progression of ag-
gressive tumor phenotypes.
The less aggressive MCF-7 breast cancer cell model generated
significant nitrite levels in response to a CM, but not by cytokines
administered as single agents (23). Herein, we show IFN-γ–
induced NOS2 and nitrite accumulation in metastatic MDA-
MB-231 breast cancer cells. Despite its role in tumor surveil-
lance, the diverse functions of IFN-γ in cancer are beginning to
emerge because of unbalanced IFN/JAK/STAT signaling, and it
is postulated to suppress tumor immune surveillance leading
to the selection of more aggressive, clinically resistant tumors
(24–26). In support of these findings, distinct aggressive tumor
phenotypes expressing high IFN-γ predict poor patient survival
(27). Also, elevated serum IFN-γ predicted cancer recurrence and
reduced disease-free survival in melanoma patients (28). Because
INF-γ up-regulates NOS2 in aggressive breast cancer cells, we
explored potential mechanistic effects linking IFN-γ signaling with
elevated NOS2 tumor expression that predicted poor breast cancer
specific survival in ER− patients (4). To accomplish this mechanistic
investigation, we examined the promoters of 44 genes up-regulated
in high NOS2 expressing tumors (4). Among these genes, our
analysis identified IFN regulatory factor-1 (IRF1) binding sites in
the promoters of the stem cell biomarker CD44 and the basal-like
breast cancer biomarker S100A8. IRF1 is also necessary for tran-
scriptional activation of the NOS2 gene (29), and this finding
implicates an IFN signature as a key mediator of NOS2 expression
and downstream effects in these aggressive breast tumors (4).
IL-8 and IL-6 are two additional biomarkers of disease pro-
gression identified in high NOS2 expressing ER− breast tumors
(4) and triple negative breast cancer patients (30). Herein, we
show IFN-γ induced the mRNA expression of IL-6 that was
abated by NOS2 inhibition via AG. Circulating IL-6 is elevated
in cancer patients and known to increase STAT3 and initiate
downstream binding of STAT and NF-κB in the NOS2 pro-
moter. This scenario provides an additional mechanism for feed-
forward NOS2 regulation within the tumor microenvironment.
IFN-γ also induced S100A8 in MDA-MB-231 cells, which was
also abolished by AG. Interestingly, AG-inhibited S100A8 mRNA
was restored to IFN-γ–induced levels by the addition of 300 μM
DETA/NO. Baseline expression of the S100A8 receptor TLR4 and
IL-8 were suppressed by AG, indicating a tight regulation of these
proteins by basal levels of NOS2-derived NO in MDA-MB-231
cells. Collectively, these results support a role of IFN-γ within the
breast cancer tumor microenvironment that promotes prosurvival
mechanisms in specific breast cancer disease states and implicates
the IFN-γ/JAK/STAT pathway as a potential therapeutic target in
ER− breast cancer patients with high NOS2 tumor expression.
Further elucidation of these and other signatures should improve
personalized therapeutic efficacy (26).
Fig. 3. NO effects on biomarker expression in MDA-MB-231 cells treated
with IFN-γ (4 h) and SW (48 h). (A–E ) mRNA expression of S100A8, IL-6, IL-8,
and TLR4 induced by IFN-γ. (F ) TIMP1 protein expression (Upper) and ni-
tration (3NT blot) of TIMP1 immuno-precipitates (Lower) in IFN-
γ–stimulated cells treated with or without AG (±SEM, *P ≤ 0.05, **P ≤ 0.01,
and ***P ≤ 0.001).
Fig. 4. Summary of NOS2 induction and its downstream signaling in ER−
breast cancer.






















Nutrient deprivation (SW) and hypoxia are also common
features of tumors and are important when considering the
regulation of inflammatory proteins associated with poor survival
(31, 32). Hypoxia increases NOS2 and COX2 mRNA in MDA-
MB-231 (16) and NOS2 mRNA in MCF-7 cells (15). Our studies
show NOS2 protein up-regulation in breast cancer cells after
24-h incubation in 1% O2. Moreover, SW increased cell migra-
tion of MDA-MB-231 cells at 1% O2 (33), and our results
(Fig. 2F) implicate NOS2 regulation as a key driver leading to
tumor cell migration under these conditions. Herein, SW alone
significantly increased NOS2 mRNA and protein in all cell lines.
In tumors, nutrient deprivation results from limited vasculari-
zation and forces tumor adaptation via activation of angiogenic,
invasion, and survival pathways (12). NO augments tumor cell
survival, implicating NOS2 as a mediator of tumor survival under
these conditions (4, 20, 34, 35). Importantly, the current study
shows positive feed-forward regulation of NOS2 protein and
mRNA expression by exogenous NO under SW conditions, be-
cause AG suppressed NOS2 levels, which then rebounded in the
presence of exogenous NO donor. We have shown that the
TIMP1 protein predicted poor breast cancer survival and acti-
vated Akt/BAD signaling in patients with high tumor NOS2
expression (20). Also, TIMP1 nitration correlated with NO-
induced PI3k/Akt/BAD prosurvival signaling in MDA-MB-231
cells (20). Herein, we show IFN-γ followed by SW-induced TIMP1
protein expression and nitration in MDA-MB-231 cells, which was
suppressed by AG. These results suggest that IFN-γ promotes
tumor survival.
The regulation of NOS2 in breast tumors depends on various
conditions that are associated with the tumor microenvironment
including cytokines, hypoxia, nutrient deprivation, and various
metabolic factors. This report presents evidence that NOS2 in-
duction may be sustained by feed-forward regulatory loops in-
volving components of the tumor microenvironment including
NO, IL-6, and COX2.
Conclusion
Herein, we show that pharmacological NOS2 inhibition abated
tumor growth and metastatic burden of aggressive MDA-MB-231
xenographs in mice. Moreover, low baseline NOS2 expression was
observed in metastatic MDA-MB-231 cells grown in culture,
which diminished by NOS2 inhibition, then reaccumulated in the
presence of exogenous NO. Similarly, NOS2 inhibition blocked
MDA-MB-231 cell migration, which was restored to basal levels
by the addition of 100 μM DETA/NO. Importantly, NOS2
inhibited cell migration was significantly enhanced above basal
levels by the addition of 300 μM DETA/NO, which suggests NO
flux-dependent regulation of tumor cell migration. Furthermore,
NO donor pretreatment or SW suppressed Taxol cell killing of
MDA-MB-231 cells, indicating the promotion of tumor survival
and chemoresistance by NOS2-derived NO. These results suggest
a requirement of feed-forward NOS2 regulation for the mainte-
nance of a basal NO flux that perpetuates protumorigenic sig-
naling leading to cancer progression and metastases.
Various stimulants present within the tumor microenviron-
ment were found to induce NOS2 expression in vitro. Toward
this end, NOS2 was induced in MCF-7, MDA-MB-468, and
MDA-MB-231; however, each cell line required different
stimulants with varied temporal profiles. Furthermore, NOS2-
induced regulation of tumor biomarkers supports NOS2 as a
biomarker of disease progression in breast cancer patients (4).
NOS2 inhibition in MDA-MB-231 cells decreased basal IL-8 and
TLR4 expression. Also, TIMP1, S100A8, and IL-6 were en-
hanced by IFN-γ in an NO-dependent manner in these cells. The
levels of NO that activate these pathways are consistent with
∼200–400 nM steady-state NO flux. These results suggest that
NOS2 can be endogenously activated and that NO donors are
a viable resource for understanding pathologic NO effects. The
heterogeneity of stimulation paradigms is reminiscent of that in
tumors and supports a role of flux-dependent NOS2-derived NO
in disease progression. The elucidation of factors within the tu-
mor microenvironment that regulate NOS2 and NO flux-driven
tumor progression could lead to more personalized therapeutic
options for women whose breast tumors express high NOS2. The
use of NOS2 inhibitors combined with inhibition of upstream
and downstream NO targets (i.e., IFN-γ/JAK/STAT, PI3K/AKT,
NF-κB, HIF-1α) or the inhibition of microRNAs that regulate
human NOS2, such as miRNA-939, could improve clinical out-
come of breast cancer patients. Moreover, NOS2 inhibition
suppressed growth and metastatic potential of KRAS mutant
MDA-MB-231 (34, 36) cells, which suggests that NOS2 in-
hibition may provide a viable option for patients with currently
untreatable RAS mutant tumors.
Materials and Methods
Cell Culture. MCF-7, MDA-MB-231, and MDA-MB-468 human breast cancer
cells (American Type Culture Collection) were maintained in RPMI 1640
media supplemented with 10% (vol/vol) heat inactivated FBS and 1% penicillin-
streptomycin in a humidified atmosphere of 5% CO2 and room air. Cells
were plated in 60-mm dishes at densities of 2 × 106 cells in 4 mL of medium
and grown overnight (80–90% confluent). For nitrite analyses, cells were
seeded at 2 × 105 in 24-well plates and grown overnight. The medium was
replaced with 2 mL (60-mm plates) or 0.5 mL (24-well plates) of serum
and phenol-free RPMI 1640 containing penicillin/streptomycin and in-
flammatory stimulants. Cytokines were added alone or as a CM of 500 U/mL
IFN-γ, 20 ng/mL TNF-α, 20 ng/mL IL-1β (R&D Systems), and 20 ng/mL LPS
(Sigma). IFN-α and -β (R&D Systems) were added at 500 U/mL hypoxia was
achieved by incubating the cells under 1% O2 and 5% CO2 in a Bactron
hypoxic chamber (Shel Lab). NOS2 activity was inhibited by the addition of
1 mM AG (Sigma), and cellular effects of NO were independently evaluated
by adding the NO donor DETA/NO (T 1/2 = 20 h at 37 °C) at various con-
centrations (Larry Keefer, National Cancer Institute-Frederick). We selected
AG as the primary tool in our studies because of its previous use in clinical
trials, its well established oral administration, and because the other common
NOS2 inhibitor, 1400W, has shown toxic effects at higher doses (37).
In Vivo Studies. Female athymic nude mice were supplied from the Frederick
Cancer Research and Development Center Animal Production Area
(Frederick, MD). The animals were received at 8 wk of age, housed five per
cage, and given autoclaved food andwater ad libitum. TheNOS2 inhibitor AG
was administered in filter-sterilized drinking water at 0.5 g/L. Animals were
injected with 750,000 GFP-tagged MDA-MB-231 human breast cancer cells in
the mammary fat pad at 9–10 wk of age and grown for 1 wk before ad-
ministration of the NOS2 inhibitor AG. Tumor volume was measured by
caliper and calculated as mm3 = [width2 × length]/2, where width is the
smaller dimension and presented as mean ± SEM and GFP fluorescence and
quantitation are described in SI Materials and Methods. Animal protocols
were approved and performed in accordance with principles outlined in the
Guide for the Care and Use of Laboratory Animals (Institute of Laboratory
Animal Resources, National Research Council).
Statistical Analyses. Results are presented as mean ± SEM and determined
from at least three independent experiments. Statistical significance was
evaluated with Student’s t tests as part of PRISM Graphpad Software and
reported as *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001.
All other methods are summarized in detail in SI Materials and Methods.
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